370 related articles for article (PubMed ID: 26791479)
1. Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.
Guntuku L; Naidu VG; Yerra VG
Curr Neuropharmacol; 2016; 14(6):567-83. PubMed ID: 26791479
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial dysfunction in gliomas.
Katsetos CD; Anni H; Dráber P
Semin Pediatr Neurol; 2013 Sep; 20(3):216-27. PubMed ID: 24331363
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma.
Di K; Lomeli N; Wood SD; Vanderwal CD; Bota DA
Oncotarget; 2016 Nov; 7(47):77457-77467. PubMed ID: 27764809
[TBL] [Abstract][Full Text] [Related]
5. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria.
Griguer CE; Oliva CR
Curr Pharm Des; 2011; 17(23):2421-7. PubMed ID: 21827418
[TBL] [Abstract][Full Text] [Related]
6. The role of mitochondria in glioma pathophysiology.
Ordys BB; Launay S; Deighton RF; McCulloch J; Whittle IR
Mol Neurobiol; 2010 Aug; 42(1):64-75. PubMed ID: 20414816
[TBL] [Abstract][Full Text] [Related]
7. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
8. Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure.
Oudard S; Boitier E; Miccoli L; Rousset S; Dutrillaux B; Poupon MF
Anticancer Res; 1997; 17(3C):1903-11. PubMed ID: 9216643
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
10. Endocytosis-mediated mitochondrial transplantation: Transferring normal human astrocytic mitochondria into glioma cells rescues aerobic respiration and enhances radiosensitivity.
Sun C; Liu X; Wang B; Wang Z; Liu Y; Di C; Si J; Li H; Wu Q; Xu D; Li J; Li G; Wang Y; Wang F; Zhang H
Theranostics; 2019; 9(12):3595-3607. PubMed ID: 31281500
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.
Liu M; Lin Y; Zhang XC; Tan YH; Yao YL; Tan J; Zhang X; Cui YH; Liu X; Wang Y; Bian XW
Lab Invest; 2017 Nov; 97(11):1354-1363. PubMed ID: 28759011
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial DNA Alterations in Glioblastoma (GBM).
Leão Barros MB; Pinheiro DDR; Borges BDN
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072607
[TBL] [Abstract][Full Text] [Related]
14. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.
Lin F; de Gooijer MC; Hanekamp D; Brandsma D; Beijnen JH; van Tellingen O
CNS Oncol; 2013 May; 2(3):271-88. PubMed ID: 25054467
[TBL] [Abstract][Full Text] [Related]
15. ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies.
Rinaldi M; Caffo M; Minutoli L; Marini H; Abbritti RV; Squadrito F; Trichilo V; Valenti A; Barresi V; Altavilla D; Passalacqua M; Caruso G
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338365
[TBL] [Abstract][Full Text] [Related]
16. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.
Wang H; Zhang SY; Wang S; Lu J; Wu W; Weng L; Chen D; Zhang Y; Lu Z; Yang J; Chen Y; Zhang X; Chen X; Xi C; Lu D; Zhao S
Neuro Oncol; 2009 Dec; 11(6):790-802. PubMed ID: 19289490
[TBL] [Abstract][Full Text] [Related]
17. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
Braun Y; Filipski K; Bernatz S; Baumgarten P; Roller B; Zinke J; Zeiner PS; Ilina E; Senft C; Ronellenfitsch MW; Plate KH; Bähr O; Hattingen E; Steinbach JP; Mittelbronn M; Harter PN
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):379-393. PubMed ID: 33080075
[TBL] [Abstract][Full Text] [Related]
18. The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic.
Scatena R; Bottoni P; Botta G; Martorana GE; Giardina B
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C12-21. PubMed ID: 17475665
[TBL] [Abstract][Full Text] [Related]
19. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
20. Targeting metabolic remodeling in glioblastoma multiforme.
Wolf A; Agnihotri S; Guha A
Oncotarget; 2010 Nov; 1(7):552-62. PubMed ID: 21317451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
